Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
small cell lung cancer
Biotech
BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC
BioNTech and BMS have picked the pumitamig dose for the Rosetta Lung-01 phase 3 trial in first-line extensive-stage small cell lung cancer.
Angus Liu
Sep 8, 2025 11:00am
Daiichi, Merck rev up for accelerated approval filing
Sep 7, 2025 10:45am
BioNTech posts survival data behind bispecific's phase 3 push
Mar 28, 2025 8:00am
Chasing Merck, BioNTech, DualityBio post first data on ADC
Dec 6, 2024 9:07am
Merck, Daiichi repeat early success in small cell lung cancer
Sep 9, 2024 10:27am
Merck stops phase 3 TIGIT trial in lung cancer for futility
Aug 8, 2024 7:49am
